Rubius Therapeutics, Inc. (RUBY)

NASDAQ: RUBY · IEX Real-Time Price · USD
+0.002 (0.68%)
Jan 27, 2023, 4:00 PM EST - Market closed

Company Description

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases.

The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers.

It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes.

The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Rubius Therapeutics, Inc.
Rubius Therapeutics logo
Country United States
Founded 2013
IPO Date Jul 18, 2018
Industry Biotechnology
Sector Healthcare
Employees 9
CEO Pablo Cagnoni

Contact Details

399 Binney Street, Suite 300
Cambridge, Massachusetts 02139
United States
Phone 617-679-9600

Stock Details

Ticker Symbol RUBY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001709401
CUSIP Number 78116T103
ISIN Number US78116T1034
Employer ID 04-2688109
SIC Code 2836

Key Executives

Name Position
Dannielle Appelhans Chief Executive Officer and Pres
Jose I. Carmona M.B.A. Principal Accounting Officer and Treasurer
Dr. Laurence A. Turka M.D. Chief Scientific Officer and Head of Research and Translational Medicine
Marissa Hanify Director of Corporate Communications

Latest SEC Filings

Date Type Title
Jan 20, 2023 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 21, 2022 8-K Current Report
Dec 14, 2022 8-K Current Report
Dec 12, 2022 8-K Current Report
Nov 9, 2022 10-Q Quarterly Report
Nov 2, 2022 8-K Current Report
Oct 17, 2022 8-K Current Report
Oct 13, 2022 8-K Current Report
Sep 13, 2022 8-K Current Report
Aug 12, 2022 8-K Current Report